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Purpose of study
• Provide the evidence for, and discuss, the merits of potential 
changes in how MS is managed:
• Use of better (and more accurate) diagnostic follow up to monitor disease 
progression
• Earlier use of disease modifying treatments to achieve better outcomes for 
individuals
• Assess the socio-economic and personal impact of such a policy 
change compared to the current status
The IMPrESS (International-MultiPlE-Sclerosis-Study)






• Differences between countries for:
• Total cost
• Direct medical costs
• Indirect costs
• Quality of life (measured by EQ-5D)
• RRMS 66%
• SPMS 11%
• PPMS 10% 
• Unknown 13% 

















Health status: Aspects identified as having a big 
impact by PWMS
Fatigue and weakness 54%
Mobility 54%




These are the top six aspects that respondents believed a 
new MS treatment should keep under control
Choosing disease modifying treatments: the most 
important three attributes














* Side effects (i.e. safety), do not currently take/want to take any medicines
Preferred source of information
0% 10% 20% 30% 40% 50% 60% 70%
MS specific websites
Family doctor





Molecule Indication Evidence from HTA agencies




IFNβ 1a IM RRMS DNL DNL LWC LWC N/A N/A
Alemtuzumab Active RRMS L L N/A L N/A DNL
IFNβ 1a SC RRMS DNL L LWC DNL N/A DNL
IFNβ 1b SC RRMS N/A L LWC N/A N/A N/A
Glatiramer acetate RRMS DNL N/A L N/A N/A N/A
Teriflunomide RRMS LWC L L LWC A DNL
Dimethyl fumarate Active RRMS LWC LWC LWC L A N/A
Fingolimod Highly active RRMS LWC L LWC LWC A LWC
Natalizumab Rapidly evolving 
severe RRMS
L L LWC DNL N/A LWC
HTA Treatment recommendations for MS 
L= Listed (accepted); LWC= Listed with criteria (restricted); DNL= Do not list (rejected); A= Assessed without decision. N/A = Not 
assessed for the indication
There is an urgent need to achieve better outcomes 
for PWMS
The evidence suggests that this is possible if policy makers address the 
following issues.
 Diagnosis, treatment and management goals should be set to provide 
the best health outcome for every person with MS
 (Further) robust evidence should be generated and used in order to 
make appropriate decisions about care management in MS strategies
 Improve the responsiveness of health care systems to new evidence 
on MS
Next steps
• Expand the number of countries and participants




• All who completed the questionnaire
• European Multiple Sclerosis Platform, MS Society UK, MS Trust UK, National 
Multiple Sclerosis Society, the Romanian Association of Multiple Sclerosis, the 
Rocky Mountain Multiple Sclerosis Center and Foundation ARSEP - French MS 
Research Society - who facilitated data collection. 
• Rozalina Lapadatu, Alessandra Ferrario, Elena Nicod and Olivier Wouters for 
translating the questionnaires. 
• Birgit Bauer and Rozalina Lapadatu for additional insights and support in the 
development of the questionnaires and facilitating their distribution to 
respondents. 
• F. Hoffmann-La Roche provided the sponsorship that allowed the LSE to carry out 
this research.
